Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and Ibrutinib vs DRC in Waldenström's Macroglobulinaemia
NCT04061512Phase 3Recruiting
- Sponsor
- University College London
- Start
- Feb 2020
- Primary completion
- Mar 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ibrutinib in Waldenström macroglobulinemia (WM) (2 arms), sponsored by University College London. Primary endpoints: Overall Response Rate at 24 weeks and Progression Free Survival at 2 years. Started Feb 2020; status: recruiting.
02
Drugs
ibrutinib
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT04061512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04061512.